神经生长因子联合糖皮质激素治疗非动脉炎性前部缺血性视神经病变的疗效  

Efficacy of nerve growth factor combined with glucocorticoid in the treatment of non-arteritic anterior ischemic optic neuropathy

作　　者：冯国丽[1] 王雪 刘永华[1] FENG Guoli;WANG Xue;LIU Yonghua(Department of Ophthalmology,Liaocheng People's Hospital,Liaocheng,Shandong,252000,China)

机构地区：[1]聊城市人民医院眼科,山东聊城252000

出　　处：《当代医学》2024年第7期39-43,共5页Contemporary Medicine

摘　　要：目的探讨神经生长因子联合糖皮质激素治疗非动脉炎性前部缺血性视神经病变的疗效。方法选取2019年11月至2021年11月聊城市人民医院收治的202例非动脉炎性前部缺血性视神经病变患者作为研究对象,按照随机数字表法分为常规组与联合组,每组101例。常规组采用糖皮质激素治疗,联合组采用神经生长因子联合糖皮质激素治疗,比较两组治疗前及治疗4周后视野平均缺损(MD)、最佳矫正视力(BCVA)、血管内皮生长因子(VEGF)、血清血管内皮素(ET-1)水平及临床疗效、并发症发生情况。结果治疗后,两组MD、BCVA低于治疗前,且联合组低于常规组,差异有统计学意义(P<0.05)。联合组治疗总有效率高于常规组,差异有统计学意义(P<0.05)。治疗后,两组VEGF、ET-1水平低于治疗前,且联合组低于常规组,差异有统计学意义(P<0.05)。随访6个月,联合组并发症发生率低于常规组,差异有统计学意义(P<0.05)。结论神经生长因子联合糖皮质激素治疗非动脉炎性前部缺血性视神经病变的疗效显著,可提高患者视力,改善视野缺损情况,有效降低血清ET-1、VEGF水平,并减少并发症发生,值得临床推广应用。Objective To investigate the efficacy of nerve growth factor combined with glucocorticoid in the treatment of non-arteritic anterior ischemic optic neuropathy.Methods 202 patients with non-arteritic anterior ischemic optic neuropathy admitted to Liaocheng People's Hospital from November 2019 to November 2021 were selected as the research subjects,and they were divided into the routine group and the combined group according to the random number table method,with 101 cases in each group.The routine group was treated with glucocorticoid,and the combined group was treated with nerve growth factor combined with glucocorticoid.The visual field mean defect(MD),best corrected visual acuity(BCVA),vascular endothelial growth factor(VEGF),serum vascular endothelin-1(ET-1)levels before and after 4 weeks of treatment,clinical efficacy and complications were compared between the two groups.Results After treatment,MD and BCVA of the two groups were lower than those before treatment,and the combined group was lower than the routine group,the differences were statistically significant(P<0.05).The total effective rate of treatment in the combined group was higher than that in the routine group,and the difference was statistically significant(P<0.05).After treat-ment,VEGF and ET-1 levels of the two groups were lower than those before treatment,and the combined group was lower than the routine group,the differences were statistically significant(P<0.05).After 6 months of follow-up,the total incidence of complications in the combined group was lower than that in the routine group,and the difference was statistically significant(P<0.05).Conclusion Nerve growth factor combined with glu-cocorticoid has significant clinical effect in the treatment of non-arteritic anterior ischemic optic neuropathy,it can improve the visual acuity and visu-al field defect of patients,effectively reduce the levels of serum ET-1 and VEGF,and reduce the occurrence of complications,which is worthy of clin-ical promotion and application.

关 键 词：神经生长因子 糖皮质激素 非动脉炎性前部缺血性视神经病变 血管内皮生长因子 

分 类 号：R774.6[医药卫生—眼科]